Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11173MR)

This product GTTS-WQ11173MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11173MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4571MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ11121MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ12881MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ14523MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ14035MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ6515MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ3513MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ13569MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRX-302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW